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psychiatric disorders (GHQ-positive). Physician (PhGA) and patient global assess-
ments were obtained. We investigated the variables involved in the QoL through a
logistic regression analysis. RESULTS: . 195 cases were analysed. 26% were GHQ-
positive, reporting an impact on health status due to acne worse respect other
chronic diseases. Males rather than females reported a poorer QoL. A GHQ-positive
status (Skindex-29 overall: OR 2.6;95% CI 1.20-5.60,p0.05, functioning:OR 2.5;95%
CI 1.17-5.44,p0.05, symptoms:OR 3.0; 95% CI 1.36-6.53,p0.01; emotions:OR 2.55;
95% CI 1.19-5.46,p0.05) and having a severe/very severe PhGA (Skindex-29 over-
all:OR 3.4; 95% CI 1.20-10.38,p0.05) were associated with a poor QoL. Age of onset
25 was linked to being GHQ-positive (OR 2.92; 95% CI 1.2-7.1, p0.05) controlling
for gender, marital status and educational level. CONCLUSIONS: . Acne is not a
minor disease in comparison with other chronic conditions. Age of patient is ca-
pable to influence GHQ status which in turn affects QoL.
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LIMITED ROLE OF MARITAL STATUS IN THE IMPACT OF DERMATOLOGICAL
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OBJECTIVES:Health status, health services utilization, andmortality differ bymar-
ital status for both sexes in most conditions, but little is known about dermatolog-
ical diseases. To evaluatewhethermarital status is associatedwith the impact that
dermatological diseases have on quality of life (QoL). METHODS: Data from two
surveys on dermatological outpatients were pooled. Marital status, sex, age, and
educational level were analysed in relation to QoL (using the scales of the Skin-
dex-29 questionnaire: emotions, symptoms, and functioning) and psychological
well-being (using the GHQ-12 questionnaire). RESULTS:We obtained data on 5471
patients (59% females, 46% married). Married patients (both males and females)
had lower mean values on the emotions scale and higher mean values in the
symptoms scale of the Skindex-29 compared to singles. Statistically significant
differences were identified only inmen, for the emotions scale and for the GHQ-12.
Females had significantly higher mean scores than males on each of the Skin-
dex-29 scales and on the GHQ-12. A multiple logistic regression model including
age, gender, and marital status, showed significant results only for gender, with
women suffering a more severe impact than men on all scales. No effect was
observed for marital status. CONCLUSIONS: Married patients had a lower disease
impact on the emotions scale even if they suffered a higher impact on the symp-
toms scale. After multiple adjustments, however, gender seems to be more rele-
vant than marital status in the evaluation of the impact of skin conditions on QoL.
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OBJECTIVES: Patient-reported outcomes (PROs) such as quality of life, satisfaction
with treatment, and health status provide the patients’ viewpoint on how their
diagnosis impacts their daily lives. In dentistry, PRO use, value and logistics in the
dental practice setting remain an area for further consideration. This paper de-
scribes the PEARL PRO characteristics and discusses their implementation in a
dental PBRN setting. METHODS: The Practitioners Engaged in Applied Research
and Learning (PEARL) network has conducted 7 clinical studies in the practice-
based setting. These studies included PROs related to: oral health impact (OHIP
-14), tooth sensitivity, pain medication, and implant esthetics questionnaire. The
Food and Drug Administration issued a Regulatory Guidance on PROs which was
used as the framework for evaluation of the PRO measures. RESULTS: Of the 7
PEARL clinical studies, all used the OHIP-14, 5 studies measured tooth sensitivity
and pain medication, and one study measured patient satisfaction. A total of 6077
patients have completed the OHIP-14 scale, 2,976 patients have completed the
tooth sensitivity questionnaire, and the implant esthetics and sensitivity question-
naires have been completed by 332 patients. PROsmeasures differed in their num-
ber of items, mode of administration, and domains. We found consistent associa-
tion between the tooth sensitivity and the OHIP-14measures across PEARL studies.
CONCLUSIONS: The value of PROs in dentistry in the context of a dental practice-
based research network (PBRN) has received limited attention. Our study found
that collecting PROs is possible and that they represent an indicator of the effec-
tiveness of a dental treatment. More work is needed to inform dental practitioners
on the value of thesemeasures and to enhance themeasurement properties of the
questionnaires. The PEARL network has used several PRO measures with diverse
characteristics to adapt to the dental practice setting and to measure the dental
condition.
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Ingenol mebutate gel is a new treatment of Actinic Keratosis (AK). The adverse
effects of current AK drug treatment involve long-lasting local skin responses
(LSRs) which may influence patient adherence negatively. OBJECTIVES: Assess
patient=s willingness-to-pay (WTP) for accessing ingenol mebutate gel instead of
imiquimod 5%, imiquimod 3.75% and diclofenac 3% in a US setting and assess
patient=s likelihood of completing a full treatment course. METHODS: A web-sur-
vey (contingent valuation design) was sent to 2000 adults, including only AK diag-
nosed subjects with self-reported AK lesions on face/scalp and/or trunk/extremi-
ties, asking them their maximum WTP to receive access to ingenol mebutate gel
instead of one of three alternative drugs. The profile was varied in three dimen-
sions; duration of treatment and treatment-related local skin responses and com-
parator price. Respondents were also asked to rank the likelihood to successfully
complete treatment course. Internal validity was checked (hypothetical drug pro-
file and income effect). RESULTS: A total of 116 subjects (105 useful) responded
(response rate 53% if AKprevalence assumed to 11%). A total of 33% stated that they
followed treatment instructions fairly well (75% of the time) or to some extent
(50%), despite experience of LSRs. Almost 90 % rated ingenol mebutate gel as the
treatment they were most likely to successfully complete; 50-63% were willing to
pay extra (mean $475-518/course) to access ingenol mebutate gel instead of the
three treatment alternatives. Subjects with experience of drug treatment stated an
incrementalWTP (mean $820/course) for accessing ingenolmebutate gel instead of
imiquimod 3.75%. Subjects currently treating the full scalp or forehead stated an
incremental WTP (mean $674 respectively $726/course) for accessing ingenol
mebutate gel instead of imiquimod 5% and diclofenac 3%. CONCLUSIONS: There is
a substantial dissatisfaction with current AK treatments and clear evidence that
patients are willing to pay for shorter treatment and LSR duration.
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OBJECTIVES: To determine dosing patterns of ustekinumab, a biologic treatment
formoderate to severe plaque psoriasis, by analyzing prescription fill data and days
supplied from Diplomat Specialty Pharmacy (DSP). Ustekinumab is delivered as a
subcutaneous injection at weeks 0, 4, and every 12 weeks thereafter in two weight
based doses: 45mg and 90mg. METHODS: A retrospective analysis was conducted
of pharmacy fill data for patients18 years receiving2 fills of ustekinumab from
DSP between October 2009 to September 2010. Based on prescribing information
(PI), the expected time between first and second dose is 28 days / a 7-days and
the expected time between subsequent doses is 84 days/ a 14-day window. For
patients receiving 1 vial or syringe per fill, dosing was assigned based upon which
strength was initially filled. For patients receiving multiple vials or syringes per fill
(e.g. 45 mg  2), dose was based on days between fills. RESULTS: A total of 711
patients met inclusion criteria; 529 (74.4%) received one vial or syringe in the first
fill. A total of 182 patients received 2 vials or syringes, 125 (68.7%) conformed to
the expected days recommended from the PI. 57 patients (8.0%) had intervals that
fell before or after the expected time. Of the 654 (529  125) patients for whom
dosing patterns could accurately be assessed, 67.1% were dosed with 45mg.
CONCLUSIONS: Over 90% of patients had prescription fill data and intervals that
allowed for dosing patterns to be determined; the majority were dosed with 45mg.
Some patients receivedmultiple 45mg vials or syringes in one shipment, therefore
their dosing may be incorrectly interpreted as higher than their actual dose. To
appropriately analyze the dosing patterns of ustekinumab, one must account for
the number of vials or syringes supplied per fill, the strength, and the days between
fills.
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OBJECTIVES: To evaluate the relationship between weight and dose for patients
initiating ustekinumab, a biologic treatment for moderate to severe plaque psori-
asis. The recommended dosing for ustekinumab is 45mg for patients 100kg or
90mg for patients 100kg delivered as a subcutaneous injection at weeks 0, 4, and
every 12 weeks thereafter. METHODS: Patients receiving ustekinumab through
Diplomat Specialty Pharmacy (DSP) were surveyed to provide their weight. Inclu-
sion criteria were: 18 years, diagnosis of psoriasis and 2 doses of ustekinumab.
DSP provided ustekinumab shipment quantities and dates. Shipped quantities and
schedule were jointly used to estimate ambiguous doses (e.g., if two 45mg doses
were in the index shipment, the index dosewas estimated to be 90mg if the second
shipment was within 3-5 weeks; the index dose was estimated to be 45mg if the
next shipment was 12-18 weeks). RESULTS: Of 257 patients surveyed, 65% (166)
weighed100kg and 35% (91) weighed100kg. Of those100kg, 83% (138) received
a single 45mg index dose; 11% (19) received a single 90mg dose. Of those 100kg,
16% (15) received a single 45mg and 59% (54) received a single 90mg dose. Thirty-
one patients received two or more 45mg doses in the index fill (9 100kg and 22
100kg). Based on timing of the second fill for those patients, the index dose was
estimated to be 45mg and 90mg for 18 and 10 patients, respectively. Three patients
receiving two 45mgdoseswere not evaluable based on second fill date. In summary
by weight, 86% (142/166) of patients weighing 100kg are estimated to have re-
ceived an index dose of 45mg and 76% (69/91) of patients100kg likely received an
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